Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Ironwood Pharmaceuticals (IRWD) over the last 17 years, with Q3 2025 value amounting to $47.6 million.

  • Ironwood Pharmaceuticals' Free Cash Flow rose 38212.58% to $47.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $67.6 million, marking a year-over-year decrease of 4536.41%. This contributed to the annual value of $103.4 million for FY2024, which is 4354.1% down from last year.
  • Per Ironwood Pharmaceuticals' latest filing, its Free Cash Flow stood at $47.6 million for Q3 2025, which was up 38212.58% from -$15.1 million recorded in Q2 2025.
  • Ironwood Pharmaceuticals' 5-year Free Cash Flow high stood at $80.2 million for Q1 2023, and its period low was -$15.1 million during Q2 2025.
  • Over the past 5 years, Ironwood Pharmaceuticals' median Free Cash Flow value was $47.6 million (recorded in 2025), while the average stood at $46.0 million.
  • Data for Ironwood Pharmaceuticals' Free Cash Flow shows a peak YoY increase of 38212.58% (in 2025) and a maximum YoY decrease of 14511.03% (in 2025) over the last 5 years.
  • Ironwood Pharmaceuticals' Free Cash Flow (Quarter) stood at $64.4 million in 2021, then grew by 22.92% to $79.2 million in 2022, then crashed by 55.03% to $35.6 million in 2023, then plummeted by 57.29% to $15.2 million in 2024, then skyrocketed by 212.74% to $47.6 million in 2025.
  • Its Free Cash Flow was $47.6 million in Q3 2025, compared to -$15.1 million in Q2 2025 and $19.9 million in Q1 2025.